Gilead Sciences Inc is > 10% Shareholder of Arcus Biosciences, Inc.. Currently has a direct ownership of 31.4 Million shares of RCUS, which is worth approximately $342 Million. The most recent transaction as insider was on Feb 18, 2025, when has been sold 1,363,636 shares (Common Stock) at a price of $11.0 per share, resulting in proceeds of $14,999,996. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 31.4M
4.54% 3M change
4.54% 12M change
Total Value Held $342 Million

GILEAD SCIENCES INC Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 18 2025
BUY
Open market or private purchase
$14,999,996 $11.0 p/Share
1,363,636 Added 4.16%
31,424,760 Common Stock
Jan 29 2024
BUY
Open market or private purchase
$319,999,995 $21.0 p/Share
15,238,095 Added 33.64%
30,061,124 Common Stock
Jun 28 2023
BUY
Open market or private purchase
$19,452,600 $19.26 p/Share
1,010,000 Added 6.38%
14,823,029 Common Stock
Jan 31 2021
BUY
Open market or private purchase
$220,350,000 $39.0 p/Share
5,650,000 Added 28.88%
13,913,029 Common Stock

Also insider at

ALVR
Allovir, Inc. Healthcare
KYTX
Kyverna Therapeutics, Inc.
XLO
Xilio Therapeutics, Inc. Healthcare
ASMB
ASSEMBLY BIOSCIENCES, INC. Healthcare
GSI

Gilead Sciences Inc

> 10% Shareholder
Foster City, CA

Track Institutional and Insider Activities on RCUS

Follow Arcus Biosciences, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RCUS shares.

Notify only if

Insider Trading

Get notified when an Arcus Biosciences, Inc. insider buys or sells RCUS shares.

Notify only if

News

Receive news related to Arcus Biosciences, Inc.

Track Activities on RCUS